Navigation Links
Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results
Date:5/7/2008

Company resumes commercial operations with first product sales since 2005

SEATTLE, May 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended March 31, 2008. Total revenues for the quarter were $3.4 million compared to $20,000 for the first quarter of 2007. Gross product sales of Zevalin(R) (Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.

Total operating expenses increased to $28.4 million for the quarter ended March 31, 2008 compared to $23.6 million for the same period in 2007 mainly as a result of increased expenses related to the creation of commercial infrastructure to support Zevalin and fees associated with capital structure advisory services. Net loss attributable to common shareholders for the quarter ended March 31, 2008, which includes a one-time inducement payment of $16.2 million to convert preferred shares into common shares, totaled $54.6 million ($0.77 per share) compared to $28.7 million ($0.76 per share) for the comparable period in 2007. The increase in net loss attributable to common shareholders was also due, in part, to an increase in interest expense and make-whole interest payments related to the 9% convertible senior notes and the loss recorded on the exchange of the 5.75% convertible senior subordinated and subordinated notes in 2008. This was offset by a gain on the derivative liability related to conversions of the 9% convertible senior notes. We also had a foreign exchange loss for the quarter ended March 31, 2008 compared to a gain for the same period in 2007.

The Company had approximately $15.3 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of March 31, 2008. This does not include $6.2 million in restricted cash held in escrow and net proceeds, before fees and expenses, of approximately $22.9 million from the issuance on April 30, 2008 of preferred stock, convertib
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for surgical ... Driven by the need for replacement of existing installations ... geographies, the market is expected to grow to $631.9 ... 8.5% from 2013 through 2018. , While revenue generation ...
(Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
(Date:8/28/2014)... August 28, 2014 Clarity PSO ... been re-certified as a federal Patient Safety Organization (PSO) ... Agency for Healthcare Research and Quality (AHRQ). Clarity PSO ... expertise and services following the true intentions of the ... , ”We are proud and eager to continue our ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... business sector recently launched a “Video” section located ... and general information on various cannabis companies in ... can find an assortment of news clips, interviews, ... and announcements. A portion of the videos can ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider ... recipes to help clients and online readers send out ... Chef Han Ashley developed variations of Roasted Veggie ... , The PreDiabetes Centers Roasted Veggie Pizza recipe is ... and features a cheese substitute–ideal for people who are ...
Breaking Medicine News(10 mins):Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3
... fall asleep swiftly if your hands and feet are warmer ... hot baths and// sleeping pills have all been put forward ... nothing beats the dilation of blood vessels in the hands ... ,Dr Kurt Krauchi and his team at the ...
... insomniacs would fare better if they kept the bed for ... A Canadian study found that taking sleeping pills worked in ... a long period. , Insomnia is defined as trouble ... early in the morning without being able to get back ...
... linked high levels of blood fats called triglycerides to ... physicians to pay closer attention to triglyceride levels.// More ... treatments to modify this stroke risk factor could further ... that drugs that lower blood fats can also prevent ...
... breast cancer patients feel better, but it won't help them ... their medical treatment lived an average// of 18 months longer. ... any longer than the 77 who got only medical treatmen. ... and emotional distress -- especially if the levels were high ...
... and other vascular diseases are the leading causes ... in depiction of stenotic, occlusive, aneurismal, inflammatory or ... (DSA) are used to depict vascular lesions with ... material.// It is the gold standard with a ...
... a common liver disease may be caused by the production ... to affect around one in four people in developed countries. ... currently untreatable, and one in ten sufferers go on to ... risk that cancer will develop in the organ.The damage caused ...
Cached Medicine News:Health News:Cure for sleepless nights 2Health News:Magnetic resonance angiography in clinical medicine 2
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 2014  Stryker Orthopaedics, the Official Joint Replacement Products of ... of joint health to golf fans at the next stop ... Bank Championship. The company,s fan destination – "The Stryker Mobility ... 9" at the TPC Boston in Norton, MA ... At the Deutsche Bank Championship, Stryker will be ...
(Date:8/28/2014)... OAKS, Calif. , Aug. 28, 2014 ... submission of a Biologics License Application (BLA) to the ... approval for the treatment of high cholesterol. Evolocumab is ... convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces ... or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Oct. 31 2011 VolitionRX Limited (VNRX.OB) ("Volition" or the ... tests, publishes the following letter to its shareholders from Cameron ... speed at which our company has been growing and the ... would like to review the past year and look forward ...
... Japan, Oct. 31, 2011 Menicon Holdings BV and ... Thea, a France-based independent ophthalmic group, announced on October ... partner to market the SOLO-care (R) contact lens solutions ... and Canada. The agreement will enable Menicon ...
Cached Medicine Technology:VolitionRX Limited Issues Update Letter to Shareholders 2VolitionRX Limited Issues Update Letter to Shareholders 3VolitionRX Limited Issues Update Letter to Shareholders 4VolitionRX Limited Issues Update Letter to Shareholders 5Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: